Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder
Stopped early · Phase 2
Conditions studied: Autism Spectrum Disorder
In brief
To determine the safety and tolerability of GWP42006 (cannabidivarin, CBDV) in children and young adults with autism spectrum disorder (ASD) and to examine the effect of GWP42006 on communication, social interactions, sleep, behavior, and cognition profiles.
Key facts
- Study ID
- NCT03849456
- Run by
- Jazz Pharmaceuticals
- People needed
- 1
- Starts
- 2020-01-07
- Expected to finish
- 2020-05-26
- Last updated by the study team
- 2022-09-02
Who can join
Age: 4 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Trial Site — Louisville, Kentucky, United States
- Clinical Trial Site — Lexington, Massachusetts, United States
- Clinical Trial Site — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.